FOI 23/085

12th February 2023

Dear

Thank you for your email.

Please note that the marketing authorisation (MA) for Lisinopril 1 mg/ml oral solution (PL 00427/0284) was granted by a Change of Authorisation Holder (CoA) on 13 May 2022.

The original MA for Lisinopril 1 mg/ml Oral Solution (PL 41094/0010) was authorised on 27 July 2015 by an incoming decentralised procedure, with Norway as the Reference Member State (RMS - NO/H/0250/001/DC).

Further information on this product, including the Public Assessment Report (PAR) is available from the Heads of Medicines Agencies MRI Product Index. A link to this is provided below:
https://mri.cts-mrp.eu/portal/details?productnumber=NO/H/0250/001

If you have a query about the information provided, please reply to this email.

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Experience Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 0203 080 6000